MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Neuronetics Cost of Revenue 2011-2025 | STIM
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Neuronetics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.5 M | 11.7 M | 11.6 M | 15.4 M | 12.4 M | 9.63 M | 6.62 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.5 M | 6.62 M | 11.8 M |
Quarterly Cost of Revenue Neuronetics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.2 M | 20.4 M | 16.2 M | - | 4.53 M | 4.27 M | 4.33 M | - | 6.12 M | 4.84 M | 4.14 M | - | 3.57 M | 4.04 M | 3.48 M | - | 3.14 M | 2.75 M | 2.22 M | 3.76 M | 2.66 M | 2.32 M | 2.81 M | 4.22 M | 4.19 M | 4.17 M | 2.81 M | 3.71 M | 3.03 M | 3.24 M | 2.46 M | 2.96 M | 2.64 M | 2.5 M | 1.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.4 M | 1.54 M | 4.94 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
6.6 M | $ 16.71 | -0.83 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 16.22 | 2.97 % | $ 175 M |  China |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
30.4 M | $ 1.57 | -3.4 % | $ 2 M | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 38.53 | -0.26 % | $ 1.07 B | USA |
 |
DarioHealth Corp.
DRIO
|
14.4 M | $ 11.99 | 0.84 % | $ 340 M | Israel |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
1.33 B | $ 66.15 | -1.22 % | $ 25.5 B | USA |
 |
Danaher Corporation
DHR
|
9.67 B | $ 226.11 | -0.17 % | $ 165 B | USA |
 |
Exact Sciences Corporation
EXAS
|
221 M | $ 101.52 | 0.01 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 26.92 | -0.81 % | $ 814 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 19.95 | -2.97 % | $ 1.07 B | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
4.18 M | $ 0.31 | -9.7 % | $ 9.1 M | USA |
 |
IQVIA Holdings
IQV
|
10 B | $ 221.67 | -0.25 % | $ 40.2 B | USA |
 |
Aspira Women's Health
AWH
|
3.86 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
1.51 B | $ 133.75 | -0.83 % | $ 21.3 B | USA |
 |
Quotient Limited
QTNT
|
20.1 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
6.63 B | $ 183.42 | 0.5 % | $ 20.4 B | USA |
 |
Myriad Genetics
MYGN
|
252 M | $ 6.96 | -3.47 % | $ 631 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.38 B | $ 261.21 | -1.12 % | $ 21.9 B | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 181.89 | -2.51 % | $ 15 B |  Irlanda |
 |
NeoGenomics
NEO
|
370 M | $ 11.99 | 1.14 % | $ 1.52 B | USA |
 |
Neogen Corporation
NEOG
|
473 M | $ 6.78 | -1.16 % | $ 1.47 B | USA |
 |
IDEXX Laboratories
IDXX
|
1.52 B | $ 698.37 | -0.83 % | $ 57.6 B | USA |
 |
Lantheus Holdings
LNTH
|
546 M | $ 67.15 | 0.79 % | $ 4.65 B | USA |
 |
Agilent Technologies
A
|
2.91 B | $ 139.73 | 0.05 % | $ 42.5 B | USA |
 |
Biomerica
BMRA
|
4.81 M | $ 2.43 | -4.8 % | $ 5.58 M | USA |
 |
Bioventus
BVS
|
184 M | $ 7.53 | -0.26 % | $ 472 M | USA |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K | Israel |
 |
Pacific Biosciences of California
PACB
|
148 M | $ 2.1 | -1.18 % | $ 533 M | USA |